Identification of the molecular bases of altered sensitivity to drugs in cells with reduced PARylation capacity that may provide novel targets for anticancer therapeutic intervention.

1) Role of PARP inhibitors as adjuvant of chemotherapeutic agents like TOP I inhibitors.

2) Involvement of p53 family proteins in the signalling of DNA damage/apoptosis induction in carcinoma cells.

3) Mechanisms underlying the synergistic role of PARP-1 and p53 family proteins.